Sera Prognostics, Inc. Announces Resignation of Nadia Altomare from the Position of Chief Commercial Officer of the Company, Effective as of June 9, 2023
May 25, 2023 at 04:17 pm
Share
Sera Prognostics, Inc. announced that on May 24, 2023, Nadia Altomare notified the Company of her intention to resign from the position of Chief Commercial Officer of the Company, effective as of June 9, 2023, and is expected to move to a consulting role to effect a smooth commercial transition.
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant motherâs risk of delivering spontaneously before 37 weeksâ gestation.
Sera Prognostics, Inc. Announces Resignation of Nadia Altomare from the Position of Chief Commercial Officer of the Company, Effective as of June 9, 2023
SERA PROGNOSTICS, INC. 
